title: Macular sensitivity change in multiple sclerosis followed with microperimetry.
abstract: OBJECTIVE
  To describe the efficacy of MP-1 in detecting early multiple sclerosis (MS) retinal lesions and in monitoring the effectiveness of treatment in terms of changes in macular sensitivity.
  
  
  METHODS
  A 21-year-old woman with MS was referred to us complaining of recurrent episodes of eyesight loss in both eyes. At ophthalmologic examination, best-corrected visual acuity was 20/25 bilaterally; ophthalmoscopy showed bilateral slight optic neuritis without swelling of the disc. Static perimetry of central visual field (30 degrees, by Octopus 101, Haag-Streit AG, Switzerland) and retinal sensitivity of the 12 central degrees (by MP-1 Micro Perimeter, Nidek Inc., Italy) were performed on the patient at that time. The micro perimeter (MP-1) showed a loss of sensitivity in the macular region with 0.28+/-0.9 dB sensitivity in the right eye and 19.42+/1.5 dB in the left. The mean fixation stability was 91% considering 2 degrees and 99% considering 4 degrees around the fixation points in the right eye, and 97% in 2 degrees and 100% in 4 degrees central degrees in the left. In the weeks that followed vision continued to get worse in both eyes, so she underwent a steroid therapy with methylprednisolone IV 1000 mg/day for 5 days and 500 mg/day for 3 days.
  
  
  RESULTS
  After 8 days of therapy the MP-1 showed a significant recovery in the right eye, with mean light sensitivity being 19.61+/-1.3 dB in the right eye and 20.0+/-0 dB in the left eye in both macular and peripapillary regions. The mean fixation stability was 100% considering 2 degrees and 100% considering 4 degrees around the fixation points in both eyes.
  
  
  CONCLUSIONS
  The MP-1 can be an interesting tool for neuro-ophthalmologists as it allows a more precise evaluation of the macular and peripapillary region, which is not easily studied with conventional automated perimetry. In MS, the presence of a subclinical form of optic nerve involvement can be demonstrated in a very early stage, and well followed by the introduction of micro perimeter testing in the standard examination protocol.
authors.affiliation: Department of Ophthalmology, S Sebastiano Hospital, Caserta, Italy. romanomario@email.it
authors.forename: M R
authors.initials: MR
authors.lastname: Romano
authors.forename: M
authors.initials: M
authors.lastname: Angi
authors.forename: F
authors.initials: F
authors.lastname: Romano
mesh_terms: D000328:Adult; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D012164:Retinal Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D014786:Vision Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D058609:Visual Field Tests / Q000379:methods*; D014794:Visual Fields
chemical_list: D005938:Glucocorticoids; D008775:Methylprednisolone